Bard formerly incorporates his business as C. R. Bard. Inc.
Charles Russell Bard sells business to John F. Willits (pictured left), Sales Manager, and Edson L. Outwin (pictured right), Accountant, for $18,000.
The 1980s brought another healthy growth spurt for Bard. In 1980 Bard continued to expand by purchasing Davol Inc. and Davol International from International Paper Company. This acquisition was significant as Davol manufactured Foley catheters, still Bard's single largest selling product. Bard also acquired Shield Healthcare Management Inc., Catheter Technology Corp. and the assets of Radi Medical Systems AB, all in the early 1980s.
Bard Canada began selling directly to hospitals in Canada.
In the early 1990s, Bard began to focus more carefully on its major markets, selling those divisions incidental to their main focus of development of single-patient-use products for diagnosis and treatment for the urological, cardiovascular, and surgical markets.
Revenues exceeded $1 billion for the first time.
Bard Canada acquired Vas-Cath Inc, located in Mississauga, Ontario.
Bard restructured globally along disease-state management lines and also made some divestments. The most significant latter move was the sale of the coronary catheter laboratory business, which included the company's angioplasty operations.
In the largest acquisition to date, Bard acquires SenoRx, Inc., providing Bard leadership products across all breast biopsy and marker segments.
Bard acquires Medivance, Inc., the market leader in the field of therapeutic hypothermia. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.
Bard acquires Lutonix, Inc., developer of a drug-coated percutaneous transluminal angioplasty (PTA) balloon. Lutonix is the first to conduct the only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease.
Bard acquires privately-held Neomend, Inc., a leading developer and supplier of sprayable surgical sealants and anti-adhesion products. This merger significantly expands the business opportunities for Bard surgical specialties in the Davol subsidiary.
Bard Acquires Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. Medafor’s Arista® MPH Hemostat, is indicated as an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical. The acquisition expands the business opportunities for Bard’s surgical specialties in its Davol subsidiary.
Bard divests Electrophysiology business and sells certain assets to Boston Scientific Corporation.
Bard acquires Rochester Medical, Inc., a leading developer and supplier of silicone urinary incontinence and urine drainage products. The merger represents a compelling strategic fit that enhances Bard’s position in the global urology homecare market.
The Lutonix® 035 Drug Coated Balloon is the first FDA-Approved Drug Coated Balloon available in the U.S. for the treatment of Femoropopliteal Occlusive Disease. The Lutonix® 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.
XENMATRIX™ AB Surgical Graft Antibacterial-Coated Regenerative Collagen Matrix is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the graft colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2 It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.
1. IMS Data, Q2 2014, 550K search, fda.gov.
2. Preclinical data on file; results may not correlate to clinical performance.
Bard acquires full ownership of its joint venture, Medicon, Inc., in Japan.
Bard acquires Liberator Medical Holdings, Inc. Liberator is a direct-to-consumer distributor of medical products classified as Durable Medical Equipment (DME).